Biotech start-up passes on expertise on future organ-on-chip technology
Interdisciplinary knowledge exchange
Dynamic42 GmbH
In practical learning units, the participants of the Dynamic42 Academy are trained in the handling of the biotech chips developed and produced in-house as well as in working with the highly developed test systems. This includes the independent creation of cell and organ models. This means that users of the organ-on-chip technology can immediately apply the systems at a high level in their own research projects. This saves time and considerable costs in individual research projects, e.g. in the field of drug testing.
Interdisciplinary knowledge exchange
The academy is aimed in particular at scientists from the fields of pharmacology, toxicology, oncology, pulmonology, pneumology, drug development and experimental virology. With this offer, Dynamic42 responds to the need to make the rapidly developing organ-on-chip technology quickly and efficiently accessible to areas of research and development.
The response from experts to the offer is positive and the demand from interested participants is constant. “We look forward to participants with the most diverse scientific questions at every course. In addition to the intensive transfer of knowledge, this always results in an insightful professional exchange. At the end, everyone goes back to their research sites enthusiastic and eager to use the techniques they have learned in their own projects. We also support our participants in this beyond the framework of the academy,” emphasises Dr. Martin Raasch, Managing Director of Dynamic42 GmbH.
Organ-on-Chip and the future of medicine
Organ-on-chip technology points the way to the future of medical research and development. It is not only suitable for testing active substances, but also for basic research or the investigation of infectious diseases. The method is used, for example, in research into lung infections. By replicating a human organ environment close to the body in the models with human tissue, the effects of infections can be precisely observed. This will open up new approaches for therapeutic questions in the future and reduce the need for animal experiments, for example in drug testing.
In addition, organ-on-chip is a suitable method for developing advanced, individualised medicines. Human organ cells are cultivated in the biotech chips on a membrane and in channels in specific arrangements. In this way, tissue samples from individual patients can be cultivated directly and examined for the respective medical interest. For example, the observation of the development of tumour cells is made possible. The findings can be transferred to individual treatment methods.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.